BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

861 related articles for article (PubMed ID: 9253321)

  • 1. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
    Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial.
    Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Alhava E; Honkanen R; Jurvelin J; Saarikoski S
    J Clin Endocrinol Metab; 1999 Feb; 84(2):546-52. PubMed ID: 10022414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen?
    Tuppurainen MT; Komulainen M; Kröger H; Honkanen R; Jurvelin J; Puntila E; Heikkinen AM; Alhava E; Saarikoski S
    Osteoporos Int; 1998; 8(1):32-8. PubMed ID: 9692075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial.
    Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Honkanen R; Saarikoski S
    Osteoporos Int; 2000; 11(3):211-8. PubMed ID: 10824236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does apolipoprotein E genotype relate to BMD and bone markers in postmenopausal women?
    Heikkinen AM; Kröger H; Niskanen L; Komulainen MH; Ryynänen M; Parviainen MT; Tuppurainen MT; Honkanen R; Saarikoski S
    Maturitas; 2000 Jan; 34(1):33-41. PubMed ID: 10687880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
    Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
    J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
    Rosen CJ; Chesnut CH; Mallinak NJ
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism.
    Guo CY; Thomas WE; al-Dehaimi AW; Assiri AM; Eastell R
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3487-91. PubMed ID: 8855790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of androgen receptor gene polymorphism to bone mineral density and fracture risk in early postmenopausal women during a 5-year randomized hormone replacement therapy trial.
    Salmén T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Pallonen H; Saarikoski S; Honkanen R; Mäenpää PH
    J Bone Miner Res; 2003 Feb; 18(2):319-24. PubMed ID: 12568409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C; Dane B; Cetin A; Erginbas M
    Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy.
    Salmén T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Saarikoski S; Honkanen R; Mäenpää PH
    J Bone Miner Res; 2000 Feb; 15(2):315-21. PubMed ID: 10703934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leucine7 to proline7 polymorphism in prepro-NPY gene and femoral neck bone mineral density in postmenopausal women.
    Heikkinen AM; Niskanen LK; Salmi JA; Koulu M; Pesonen U; Uusitupa MI; Komulainen MH; Tuppurainen MT; Kröger H; Jurvelin J; Saarikoski S
    Bone; 2004 Sep; 35(3):589-94. PubMed ID: 15336593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.
    Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.
    Alexandersen P; Riis BJ; Christiansen C
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3013-20. PubMed ID: 10487657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up.
    Tuppurainen M; Härmä K; Komulainen M; Kiviniemi V; Kröger H; Honkanen R; Alhava E; Jurvelin J; Saarikoski S
    Maturitas; 2010 Aug; 66(4):423-30. PubMed ID: 20547017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers.
    Gallagher JC; Rapuri PB; Haynatzki G; Detter JR
    J Clin Endocrinol Metab; 2002 Nov; 87(11):4914-23. PubMed ID: 12414850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
    Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
    Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.